Goal

To evaluate the efficacy and safety of Dupilumab in reducing gastric and duodenal eosinophil counts and improving symptoms in patients with EoG with or without EoD.

Background

- Eosinophilic gastritis (EoG) and duodenitis (EoD) are chronic inflammatory disorders involving eosinophilic infiltration of the GI tract.
- Symptoms include abdominal pain, nausea, bloating, and diarrhea.
- No FDA-approved treatments currently exist for EoG/EoD.
- Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, has shown promise in eosinophilic diseases (e.g., eosinophilic esophagitis).


Implementation


- Patients were randomized to receive Dupilumab weekly, every 2 weeks, or placebo for 24 weeks (Part A/B).
- All patients transitioned to open-label Dupilumab in Part C (24-52 weeks).
- Outcomes measured: histologic remission (≤ 6 eos/hpf), symptom scores, and adverse events.
- Data shown here reflects global study arms while Duke Health continues recruitment.

between participants at baseline and after receiving either placebo or Dupilumab treatment after 24 weeks. Expected Results: Dupilumab group is expected to show the most substantial reduction in eosinophil counts versus baseline or placebo. Limitations: Participants receiving placebo in Part A or B are later transitioned to active Dupilumab in Part C. While ethically appropriate, this crossover design can make long-term comparisons between original treatment arms less clear.


Efficacy and Safety of Dupilumab in Patients with Eosinophilic Gastritis with or without Eosinophilic Duodenitis

Vivian Tang, BS, Nicole Pavlus, BS, Christy Walters, RN, David A. Leiman, MD, MSHP





Purpose: To visualize and compare the mean eosinophil counts



Baseline (day 1)